Physician profile
Michael Sands
NPI 1558551358
$2,761.61
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.99 · 2020: $326 · 2021: $828 · 2022: $448 · 2023: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.94 | 2020-2023 | Vraylar, Qulipta, Viberzi |
| Novo Nordisk INC | $408.50 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $234.41 | 2019-2022 | |
| Lilly USA, LLC | $212.68 | 2021-2023 | Mounjaro, Jardiance |
| Amgen INC. | $147.28 | 2020-2023 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $107.77 | 2020-2023 | Veozah |
| Merck Sharp & Dohme LLC | $103.45 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.29 | 2020-2023 | Jardiance, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $68.19 | 2020-2022 | |
| Abbott Laboratories | $62.61 | 2022-2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $62.44 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $56.52 | 2023 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $49.87 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.38 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $38.98 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sands listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.